Roche Lung Cancer Drug Reduced Risk of Recurrence, Death in Late-Stage Trial
18 Octubre 2023 - 1:14AM
Noticias Dow Jones
By Adria Calatayud
Roche Holding's Alecensa drug reduced the risk of disease
recurrence or death in a phase 3 trial for a type of non-small cell
lung cancer at an early stage, the company said Wednesday.
The Swiss pharmaceutical giant said a primary analysis of the
study results showed Alecensa reduced the risk of disease
recurrence or death by 76% compared with platinum-based
chemotherapy, demonstrating a statistically significant and
clinically meaningful improvement in disease-free survival.
The safety and tolerability of the drug in the trial were
consistent with previous studies and no unexpected safety findings
were observed, Roche said.
The company said it is conducting further analysis of overall
survival estimates given that data were immature at this stage.
Roche will submit data from the trial to global health
authorities, including the U.S. Food and Drug Administration and
the European Medicines Agency, it said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 18, 2023 01:59 ET (05:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Roche (QX) (USOTC:RHHBY)
Gráfica de Acción Histórica
De May 2023 a May 2024
Real-Time news about Roche Holdings Ltd AG (QX) (OTCMarkets): 0 recent articles
Más de Roche Holdings Ltd AG (QX) Artículos de Noticias